All Releases
 |
Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman
May 16, 2012
|
13.0 KB |
| |
MONMOUTH JUNCTION, N.J., May 16, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman of the Company's Board of Directors, and Randall Whitcomb, M.D. as the Lead Independent Director, effective immediately. Mr. Hayden has served as C...
|
|
Insmed Announces First Quarter 2012 Financial Results
May 8, 2012
|
24.0 KB |
| |
MONMOUTH JUNCTION, N.J., May 8, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2012.
Key Recent Highlights:
U.S. Food and Drug Administration (FDA) lifted clinical hold on ARIKACE® (liposomal amikacin for inhalation) in Cystic ...
|
|
Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
May 7, 2012
|
11.6 KB |
| |
MONMOUTH JUNCTION, N.J., May 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE® (liposomal amikacin for inhalation) in Cystic Fibrosis (CF) patients with Pseudomonas lung infection...
|
|
Insmed to Host 2012 First Quarter Earnings Conference Call
Apr 24, 2012
|
10.4 KB |
| |
MONMOUTH JUNCTION, N.J., April 24, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 8th, 2012, at 8:30 AM ET, to discuss its financial results for the first quarter of 2012. Insmed intends to issue its quarterly financial results press release before the market ope...
|
|
Insmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections
Apr 16, 2012
|
13.2 KB |
| |
MONMOUTH JUNCTION, N.J., April 16, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the initiation of the Company's CLinical Evaluation of ARIKACE phase 3 study (CLEAR-108) of ARIKACE® (liposomal amikacin for inhalation) in Europe for Cystic Fibrosis (CF) patients with Pseudomonas aerugin...
|
|
Insmed Announces Fourth Quarter and Full-Year 2011 Financial Results
Mar 13, 2012
|
28.0 KB |
| |
MONMOUTH JUNCTION, N.J., March 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011.
Key Recent Highlights:
Clinical hold lifted by U.S. Food and Drug Administration (FDA) for ARIKACE® (liposomal amikacin for inha...
|
|
Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
Feb 28, 2012
|
10.6 KB |
| |
MONMOUTH JUNCTION, N.J., Feb. 28, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, March 13th, 2012, at 8:30 AM ET, to discuss its financial results for the fourth quarter and year-end 2011. Insmed intends to issue its quarterly and year-end financial results press rel...
|
|
Insmed Incorporated Provides Update on Clinical Program for ARIKACE®
Feb 10, 2012
|
13.4 KB |
| |
MONMOUTH JUNCTION, N.J., Feb. 10, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company is proceeding with a phase 2 clinical trial of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease, as well as the previously plann...
|
|
Insmed Incorporated Provides Corporate Update
Jan 20, 2012
|
11.7 KB |
| |
MONMOUTH JUNCTION, N.J., Jan. 20, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disea...
|
|
Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Nov 14, 2011
|
10.1 KB |
| |
MONMOUTH JUNCTION, N.J., Nov. 14, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, November 16, 2011, at 8:30 AM ET, in New Yo...
|
|
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2011
Nov 8, 2011
|
26.6 KB |
| |
MONMOUTH JUNCTION, N.J., Nov. 8, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended September 30, 2011.
Key Recent Highlights:
FDA clinical hold remains in place in the U.S. for ARIKACE® (liposomal amikacin for inhalation) p...
|
|
Insmed to Host 2011 Third Quarter Earnings Conference Call
Oct 25, 2011
|
11.0 KB |
| |
MONMOUTH JUNCTION, N.J., Oct. 25, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, November 8th, 2011, at 8:30 AM ET, to discuss its financial results for the third quarter of 2011. Insmed intends to issue its quarterly financial results press release before the market...
|
|
Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
Oct 14, 2011
|
11.7 KB |
| |
MONMOUTH JUNCTION, N.J., Oct. 14, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the clinical hold previously placed on Insmed's phase 3 clinical trial for ARIKACE® (liposomal amikaci...
|
|
Insmed Incorporated Provides Regulatory Update
Oct 10, 2011
|
11.7 KB |
| |
MONMOUTH JUNCTION, N.J., Oct. 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the clinical hold previously placed on Insmed's phase 3 clinical trials for ARIKACE® (liposomal amikac...
|
|
Insmed to Present at Sixth Annual JMP Securities Healthcare Conference
Sep 26, 2011
|
10.1 KB |
| |
MONMOUTH JUNCTION, N.J., Sept. 26, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the Sixth Annual JMP Securities Healthcare Conference on Wednesday, September 28, 2011, at 11:30 AM ET, in New York....
|
|
Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
Aug 11, 2011
|
10.0 KB |
| |
MONMOUTH JUNCTION, N.J., Aug. 11, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the 2011 Wedbush Securities Life Sciences Management Access Conference on Tuesday, August 16, 2011, at 8:00 AM ET, in...
|
|
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
Aug 8, 2011
|
25.8 KB |
| |
MONMOUTH JUNCTION, N.J., Aug. 8, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2011.
Key Recent Highlights:
Announced positive results through six cycles of data from the open-label phase 2 study of Arikace™ (liposomal ...
|
|
Insmed Incorporated Announces Clinical Hold on ARIKACE® Phase 3 Clinical Trials
Aug 1, 2011
|
11.3 KB |
| |
MONMOUTH JUNCTION, N.J., Aug. 1, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical hold on Insmed's phase 3 clinical trials for ARIKACE® (liposomal amikacin for inhalation) in Cy...
|
|
Insmed to Host 2011 Second Quarter Earnings Conference Call
Jul 26, 2011
|
10.6 KB |
| |
MONMOUTH JUNCTION, N.J., July 26, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Monday, August 8th, 2011, at 8:30 AM ET, to discuss its financial results for the second quarter of 2011. Insmed intends to issue its quarterly financial results press release before the market o...
|
|
Andrea Drucker Joins Insmed as General Counsel
Jul 18, 2011
|
11.4 KB |
| |
MONMOUTH JUNCTION, N.J., July 18, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that Andrea ("Andi") Holtzman Drucker, J.D. has been appointed to the newly created position of Senior Vice President, General Counsel and Corporate Secretary, effective as of July 18, 2011. Ms. Drucker, who wi...
|
|
|
